biomedicina slovenica


"Cetuximab" : 33

  1. Saba Nabil F.; Mody Mayur D.; Tan Elaine S.; Gill Harpaul S.; Rinaldo Alessandra; Takes Robert P.; Strojan Primož; Hartl Dana M.; Vermorken Jan B.; Haigentz Missak; Ferlito Alfio
    Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN)
    2017
  2. Hofheinz Ralf-Dieter; Deplanque Gaël; Komatsu Yoshito; Kobayashi Yoshimitsu; Ocvirk Janja; Racca Patrizia; Guenther Silke; Zhang Jun; Lacouture Mario E.; Jato Eminah
    Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors
    2016
  3. Mesti Tanja; Ebert Moltara Maja
    Kolorektalni rak
    2009
  4. Ciuleanu Tudor; Scheithauer W.; Kurteva G.; Ocvirk Janja; Koza I.; Papamichael D.; Wenczl M.; Brodowicz Thomas; Beslija Semir; Zielinski Christoph C.
    A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    2008
  5. Ciuleanu Tudor; Ocvirk Janja
    A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    2008
  6. Hu-Lieskovan Siwen; Velenik Vaneja
    Use of EGF a+61G and TS-5'UTR 2R/3R polymorphisms to predict complete pathologic response in locally advanced rectal cancer patients undergoing preoperative cetuximab-based chemoradiation followed by surgery
    2010
  7. Vallbohmer D.; Velenik Vaneja
    Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in advanced rectal cancer
    2010
  8. Ocvirk Janja; Reberšek Martina
    Treatment of cetuximab-associated cutaneous side effects using topical aplication [!] oh [!] vitamin K1 cream
    2009
  9. Koza I.; Ocvirk Janja
    Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX+C) or FOLFIRI + cetuximab (FF+C)
    2009
  10. Velenik Vaneja; Ocvirk Janja; Oblak Irena; Anderluh Franc
    Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer
    2009
  11. Velenik Vaneja; Ocvirk Janja; Oblak Irena; Anderluh Franc
    Phase II XERT trial: neoadjuvant cetuximab, capecitabine and radiotherapy (RT) in locally advanced resectable rectal cancer
    2009
  12. Ciuleanu Tudor; Ocvirk Janja
    A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer
    2007
  13. Velenik Vaneja; Ocvirk Janja; Oblak Irena; Anderluh Franc
    Preoperative radiotherapy, capecitabine and cetuximab for locally advanced rectal cancer
    2011
  14. Velenik Vaneja; Ocvirk Janja; Oblak Irena; Anderluh Franc
    Five-year results of the XERT phase II trial
    2014
  15. Strojan Primož; Žumer Barbara; Karner Katarina Barbara; Grašič-Kuhar Cvetka; Jančar Boris; Fajdiga Igor; Zakotnik Branko
    Concomitant cisplatin (CP)/cetuximab (CMb) chemoradioctherapy (ChT-RT) with induction TPF ChT in stage IV inoperable squamous cell carcinoma of the head and neck (SCC-HN)
    2012
  16. Strojan Primož; Grašič-Kuhar Cvetka; Žumer Barbara; Kadivec Maksimiljan; Karner Katarina Barbara; Fajdiga Igor; Jančar Boris; Gale Nina; Poljak Mario; Kocjan Boštjan; Zakotnik Branko
    TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck
    2014
  17. Strojan Primož; Zakotnik Branko; Žumer Barbara; Grašič-Kuhar Cvetka; Karner Katarina Barbara; Fajdiga Igor; Jančar Boris
    Uvodna kemoterapija in sočasna radiokemoimunoterapija s cisplatinom in cetuksimabom pri neoperabilnem raku glave in vratu
    [Induction chemotherapy and concomitant radiochemoimmunotherapy with cisplatin and cetuximab in inoperable cancer of head and neck]
    2012
  18. Ocvirk Janja; Boc Marko; Reberšek Martina; Mesti Tanja; Ebert Maja
    Efficacy and safety of XELIRI plus cetuximab versus XELOX plus cetuximab in first-line treatment of metastatic colorectal cancer (mCRC)
    2011
  19. Ocvirk Janja; Reberšek Martina; Boc Marko; Mesti Tanja; Ebert Maja
    Prophylactic use of K1 cream for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC)
    2010
  20. Ocvirk Janja; Reberšek Martina
    Managing cutaneous side effects with K1 vitamine creme reduces cutaneous toxicities induced by cetuximab
    2008
  21. Ocvirk Janja; Heeger Steffen; McCloud Philip; Hofheinz Ralf-Dieter
    #A #review of the treatment options for skin rash induced by EGFR-targeted therapies
    2013
  22. Ocvirk Janja; Ebert Maja; Mesti Tanja; Boc Marko; Reberšek Martina
    #The #prophylactic use of K1 cream for reduction of skin toxicity during the cetuximab treatment
    2012
  23. Grašič-Kuhar Cvetka; Zakotnik Branko; Žumer Barbara; Karner Katarina Barbara; Jančar Boris; Strojan Primož
    Induction TPF chemotherapy followed by concomitant RT, cetuximab and cisplatin for inoperable HN-SCC
    2011
  24. Modest Dominik P.; Brodowicz Thomas; Stintzing Sebastian; Jung Andreas; Neumann Jens; Laubender R. P.; Ocvirk Janja; Kurteva G.; Papai Z.; Knittelfelder R.; Kirchner Thomas; Heinemann V.; Zielinski Christoph C.
    Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy
    2012
  25. Velenik Vaneja; Ocvirk Janja; Oblak Irena; Anderluh Franc
    Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial
    2012
  26. Hu-Lieskovan Siwen; Bračko Matej; Velenik Vaneja
    EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients
    2011
  27. Ocvirk Janja
    Management of cetuximab-induced skin toxicity with prophylactic use of topical vitamin K1 cream
    2010
  28. Ocvirk Janja
    Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
    2010
  29. Ocvirk Janja; Cencelj Simona
    Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer
    2010
  30. Velenik Vaneja; Ocvirk Janja; Oblak Irena; Anderluh Franc
    A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer
    2010
  31. Ocvirk Janja; Reberšek Martina
    Management of cutaneous side effectsof cetuximab therapy with vitamin K1 creme
    [Obvladovanje neželenih učinkov na kožo s kremo z vitaminom K1 pri bolnikih zdravljenih s cetuksimabom]
    2008
  32. Ocvirk Janja; Reberšek Martina; Velenik Vaneja
    Onkološko zdravljenje bolnikov z rakom debelega črevesa in danke
    [Onkology treatment for patients with colon and rectal cancer]
    2007
  33. Ocvirk Janja
    Zdravljenje bolnikov z rakom debelega črevesa
    [Treatment for patients with colon cancer]
    2006



New search      Comments      Top of page Institute for Biostatistics and Medical Informatics